Document Detail

Supplementation of glutamine and omega-3 polyunsaturated fatty acids as a novel therapeutic intervention targeting metabolic dysfunction and exercise intolerance in patients with heart failure.
MedLine Citation:
PMID:  22082326     Owner:  NLM     Status:  MEDLINE    
With its increasing prevalence throughout the world, heart failure continues to be associated with high morbidity and mortality. Patients with heart failure develop progressive metabolic abnormalities, inflammation, and atrophy in the myocardium and skeletal muscle. Improvement in functional capacity as defined by exercise tolerance is essential for better quality of life and potentially survival of these patients. Therapeutic management options aimed at improving peripheral organ function are limited. Nutritional approaches with dietary supplementation in addition to current therapies are particularly appealing as they are novel and mechanistically different. In this article, we review the role of glutamine and omega-3 polyunsaturated fatty acids on metabolism and functional capacity in heart failure. These two compounds are of particular interest due to their synergistic role on oxidative metabolism, lipolysis and inflammation.
Khurram Shahzad; Aalap Chokshi; P Christian Schulze
Related Documents :
21631836 - Resistance exercises for health promotion in coronary patients: evidence of benefits an...
2540146 - Effect of exercise duration on density and coupling of beta-adrenergic receptors on hum...
7753426 - Influence of beta-blockade with metoprolol on symptoms and functional capacity of patie...
10526196 - Further study on the specificity and incidence of neutralizing antibodies to interferon...
25103686 - Effectiveness and cost-effectiveness of a blended exercise intervention for patients wi...
24438516 - Aerobic exercise increases phosphate removal during hemodialysis: a controlled trial.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Current clinical pharmacology     Volume:  6     ISSN:  2212-3938     ISO Abbreviation:  Curr Clin Pharmacol     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-12-13     Completed Date:  2012-04-09     Revised Date:  2012-05-24    
Medline Journal Info:
Nlm Unique ID:  101273158     Medline TA:  Curr Clin Pharmacol     Country:  United Arab Emirates    
Other Details:
Languages:  eng     Pagination:  288-94     Citation Subset:  IM    
Department of Medicine, Division of Cardiology, New York-Presbyterian Hospital/Columbia University MedicalCenter, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Dietary Supplements
Drug Synergism
Exercise Tolerance
Fatty Acids, Omega-3 / pharmacology*,  therapeutic use
Glutamine / pharmacology*,  therapeutic use
Heart Failure / drug therapy*,  physiopathology
Inflammation / drug therapy,  physiopathology
Lipolysis / drug effects
Metabolic Diseases / drug therapy,  etiology
Quality of Life
Grant Support
Reg. No./Substance:
0/Fatty Acids, Omega-3; 56-85-9/Glutamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancer...
Next Document:  Drug-induced anemia and other red cell disorders: a guide in the age of polypharmacy.